Conference Roundup

Updated results of the MISSION Study presented at ACR Convergence 2020

KZR-616, a first-in-class selective immunoproteasome inhibitor, demonstrated a favorable safety and tolerability profile in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), according to data presented at ACR Convergence 2020. In the Phase 1b portion of the MISSION study, 41 patients with SLE, including 2 patients with active LN,...